Page last updated: 2024-08-23

razoxane and etoposide

razoxane has been researched along with etoposide in 44 studies

Research

Studies (44)

Timeframe	Studies, this research(%)	All Research%
pre-1990	9 (20.45)	18.7374
1990's	15 (34.09)	18.2507
2000's	18 (40.91)	29.6817
2010's	2 (4.55)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M	1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
Carter, SK; Slavik, M	1
Grieder, A; Maurer, R; Stähelin, H	1
Brunner, KW; Cavalli, F	1
Cavalli, F	1
Copplestone, JA; Hamblin, TJ; Mufti, GJ; Oscier, DG	1
Pawlicki, M; Zuchowska-Vogelgesang, B	1
Davey, P; Tudhope, GR	1
Darlow, S; Hamblin, TJ; Mufti, GJ; Nightingale, A; Oscier, DG	1
Arsenau, JC; Blessing, J; Lewis, GC; Slavik, M	1
Azuma, Y; Kizaki, H; Onishi, Y	1
Demant, EJ; Friche, E; Holm, B; Jensen, PB; Sehested, M; Sørensen, BS	1
Holm, B; Jensen, PB; Sehested, M	2
Jensen, PB; Sehested, M	2
Allan, WP; Fattman, CL; Hasinoff, BB; Yalowich, JC	1
Anderson, H; Roberge, M	1
Allan, WP; Creighton, AM; Fattman, CL; Hasinoff, BB; Kuschak, TI; Thampatty, P; Yalowich, JC	1
Allan, WP; Creighton, AM; Hasinoff, BB; Kozlowska, H; Thampatty, P; Yalowich, JC	1
Kizaki, H; Onishi, Y	1
Creighton, AM; Holm, B; Jensen, LH; Jensen, PB; Kenwrick, S; Nitiss, JL; Oliveri, RS; Sehested, M; Wessel, I	1
Ciesielska, E; Denny, WA; Gniazdowski, M; Pastwa, E; Piestrzeniewicz, MK; Szmigiero, L	1
Beck, WT; Mo, YY	1
Falck, J; Jensen, LH; Jensen, PB; Nitiss, JL; Roerth, M; Rose, A; Sehested, M; Wessel, I	1
Beck, WT; Cadena, RS; Morgan, SE; Raimondi, SC	1
Jensen, LH; Jensen, PB; Møller, M; Nitiss, JL; Sehested, M; Wessel, I	1
Barret, JM; Etiévant, C; Hill, BT; Kruczynski, A; van Hille, B	1
Alpert, L; Chalifour, LE; Kirby, GM; Mitmaker, B; Saadane, N; Yue, P	1
Barnabé, N; Hasinoff, BB	1
Cocker, HA; Kelland, LR; Pinkerton, CR; Pritchard-Jones, K; Tiffin, N	1
Berger, NA; Chatterjee, S; Gosky, D; Hirota, H	1
Hasinoff, BB; Hofland, KF; Jensen, PB; Langer, SW; Schroeder, PE; Sehested, M	2
Agostinho, M; Braga, J; Ferreira, F; Ferreira, J; Rino, J; Steffensen, S	1
Hofland, KF; Jensen, PB; Sehested, M; Thougaard, AV	1
Dejligbjerg, M; Hofland, KF; Jensen, LH; Jensen, PB; Kristjansen, PE; Rengtved, P; Sehested, M; Thougaard, AV	1
Grauslund, M; Hasinoff, BB; Jensen, LH; Liang, H; Sehested, M; Shoemaker, R	1
Hasinoff, BB; Liang, H; Wu, X; Yalowich, JC	1
Agostinho, M; Cardoso, J; Costa, R; Ferreira, F; Ferreira, J; Hay, RT; Jaffray, E; Pinheiro, I; Rino, J; Santos, V	1
Al-Anteet, AA; Al-Harbi, MM; Al-Rasheed, NM; Alhaider, AA; Attia, SM	1
Antonelli, A; Carpi, A; Cervetti, G; Fallahi, P; Franzoni, F; Galetta, F; Petrini, M; Regoli, F; Santoro, G; Tocchini, L	1
Chauvenet, A; de Alarcón, PA; Fitzgerald, TJ; Hutchison, RE; London, WB; Mendenhall, NP; Schwartz, C; Tebbi, CK; Williams, JL	1

Reviews

4 review(s) available for razoxane and etoposide

Article	Year
Investigational drugs under study by the United States National Cancer Institute. Cancer treatment reviews, 1976, Volume: 3, Issue:1 Topics: Acrylates; Alkylating Agents; Ancitabine; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Chemical Phenomena; Chemistry; Chromomycins; Cisplatin; DNA, Neoplasm; Drug Evaluation, Preclinical; Etoposide; Humans; Ifosfamide; Leukemia L1210; Mice; Mitosis; National Institutes of Health (U.S.); Neoplasms; Neoplasms, Experimental; Razoxane; Tegafur; Teniposide; United States	1976
[New substances in oncologic therapy]. Schweizerische medizinische Wochenschrift, 1978, Aug-12, Volume: 108, Issue:32 Topics: Alkylating Agents; Altretamine; Antimetabolites, Antineoplastic; Cisplatin; Dacarbazine; Doxorubicin; Drug Evaluation; Drug Evaluation, Preclinical; Etoposide; Humans; Neoplasms; Nitrosourea Compounds; Razoxane; Tamoxifen; Vinca Alkaloids; Zinostatin	1978
[New antineoplastic agents, their value and use]. Przeglad lekarski, 1982, Volume: 39, Issue:8 Topics: Aminacrine; Antineoplastic Agents; Aspartic Acid; Cisplatin; Etoposide; Humans; Ifosfamide; Interferons; Medroxyprogesterone; Medroxyprogesterone Acetate; Methyltestosterone; Neoplasms; Phosphonoacetic Acid; Razoxane; Tamoxifen; Teniposide; Vinca Alkaloids	1982
DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide. Biochemical pharmacology, 1997, Oct-01, Volume: 54, Issue:7 Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Etoposide; Humans; Mice; Razoxane; Topoisomerase II Inhibitors	1997

Trials

4 trial(s) available for razoxane and etoposide

Article	Year
[New substances in oncologic therapy]. Deutsche medizinische Wochenschrift (1946), 1978, Jul-07, Volume: 103, Issue:27 Topics: Altretamine; Ancitabine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cisplatin; Clinical Trials as Topic; Dacarbazine; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; Mitolactol; Nitrosourea Compounds; Razoxane; Remission, Spontaneous; Tamoxifen; Time Factors; Vinca Alkaloids; Zinostatin	1978
Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent. Cancer chemotherapy and pharmacology, 2004, Volume: 53, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carcinoma, Small Cell; Catheters, Indwelling; Chromatography, High Pressure Liquid; Etoposide; Humans; Infusions, Intravenous; Lung Neoplasms; Razoxane	2004
In vitro and in vivo study on the antioxidant activity of dexrazoxane. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2010, Volume: 64, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bleomycin; Chromans; Cyclophosphamide; Cytarabine; Epirubicin; Etoposide; Female; Free Radical Scavengers; Glutathione; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Razoxane; Time Factors; Uric Acid; Vincristine	2010
Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatric blood & cancer, 2012, Dec-15, Volume: 59, Issue:7 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Disease-Free Survival; Dose Fractionation, Radiation; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Male; Razoxane; Remission Induction; Survival Rate; Vincristine; Young Adult	2012

Other Studies

36 other study(ies) available for razoxane and etoposide

Article	Year
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21 Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship	2008
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
Comparative study of early effects of epipodophyllotoxin derivatives and other cytostatic agents on mastocytoma cultures. Cancer research, 1977, Volume: 37, Issue:9 Topics: Antineoplastic Agents; Bleomycin; Cell Division; Cell Line; Colchicine; Cytarabine; DNA, Neoplasm; Etoposide; Mast-Cell Sarcoma; Mechlorethamine; Mercaptopurine; Methotrexate; Mitosis; Neoplasm Proteins; Neoplasms, Experimental; Podophyllotoxin; Razoxane; RNA, Neoplasm; Teniposide; Vincristine; X-Rays	1977
Monocytic skin infiltration in chronic myelomonocytic leukaemia. Clinical and laboratory haematology, 1986, Volume: 8, Issue:2 Topics: Aged; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Monocytes; Razoxane; Skin Neoplasms	1986
Anticancer chemotherapy. British medical journal (Clinical research ed.), 1983, Jul-09, Volume: 287, Issue:6385 Topics: Alkylating Agents; Altretamine; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Etoposide; Humans; Mitobronitol; Mitolactol; Nitrosourea Compounds; Razoxane; Vinca Alkaloids	1983
Serous effusions in monocytic leukaemias. British journal of haematology, 1984, Volume: 58, Issue:3 Topics: Aged; Ascitic Fluid; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Razoxane	1984
Phase II studies in advanced, recurrent pelvic malignancies: conducted by the Gynecologic Oncology Group, Experimental Design and Experience. American journal of clinical oncology, 1982, Volume: 5, Issue:5 Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Dianhydrogalactitol; Drug Evaluation; Etoposide; Female; Humans; Maytansine; Neoplasm Recurrence, Local; Pelvic Neoplasms; Piperazines; Razoxane; Research Design; Triazines	1982
bis(2,6-dioxopiperaxine) derivatives, topoisomerase II inhibitors which do not form a DNA cleavable complex, induce thymocyte apoptosis. Biochemistry and molecular biology international, 1994, Volume: 32, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; Cells, Cultured; Cycloheximide; Dactinomycin; DNA Damage; Dose-Response Relationship, Drug; Etoposide; Gene Expression Regulation; Male; Mice; Mice, Inbred BALB C; Nucleic Acid Conformation; Piperazines; Razoxane; Thymus Gland; Topoisomerase I Inhibitors	1994
Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochemical pharmacology, 1993, Aug-03, Volume: 46, Issue:3 Topics: Cell Survival; Daunorubicin; DNA Damage; DNA Topoisomerases, Type II; DNA, Single-Stranded; Drug Interactions; Etoposide; Humans; Razoxane; Tumor Cells, Cultured	1993
ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors. Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:3 Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Ehrlich Tumor; Central Nervous System Neoplasms; DNA Topoisomerases, Type II; Etoposide; Female; Injections, Intraperitoneal; Lethal Dose 50; Leukemia L1210; Male; Mice; Mice, Inbred DBA; Paclitaxel; Razoxane; Structure-Activity Relationship	1996
Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochemical pharmacology, 1996, Apr-12, Volume: 51, Issue:7 Topics: Aclarubicin; Blotting, Western; Diterpenes; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Humans; Lung Neoplasms; Razoxane; Tumor Cells, Cultured	1996
Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells. Biochemical pharmacology, 1996, Aug-23, Volume: 52, Issue:4 Topics: Alkenes; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Humans; Leukemia; Polyenes; Pyrones; Razoxane; Thiobarbiturates	1996
Topoisomerase II inhibitors affect entry into mitosis and chromosome condensation in BHK cells. Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research, 1996, Volume: 7, Issue:1 Topics: Aclarubicin; Alkenes; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Cycle Proteins; Cell Line; Chromosomes; Cricetinae; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; G2 Phase; Guanine Nucleotide Exchange Factors; Kidney; Mitosis; Nuclear Proteins; Okadaic Acid; Phosphoprotein Phosphatases; Polyenes; Pyrones; Razoxane; Temperature; Thiobarbiturates; Topoisomerase II Inhibitors	1996
Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Biochemical pharmacology, 1997, Jun-15, Volume: 53, Issue:12 Topics: Aclarubicin; Animals; CHO Cells; Cricetinae; DNA Topoisomerases, Type II; Drug Resistance; Ethylenediamines; Etoposide; Glycine; Mutation; Razoxane; Thiobarbiturates; Topoisomerase II Inhibitors; Verapamil	1997
Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site. Molecular pharmacology, 1997, Volume: 52, Issue:5 Topics: Animals; Antineoplastic Agents; CHO Cells; Cricetinae; Diketopiperazines; DNA; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Indoles; Isoindoles; Piperazines; Razoxane; Topoisomerase II Inhibitors	1997
Topoisomerase II inhibitor-induced apoptosis in thymocytes and lymphoma cells. Advances in enzyme regulation, 1997, Volume: 37 Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Apoptosis; Base Sequence; Cell Cycle; Cells, Cultured; DNA Fragmentation; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; Gene Expression Regulation; Heterogeneous Nuclear Ribonucleoprotein A1; Heterogeneous-Nuclear Ribonucleoprotein Group A-B; Heterogeneous-Nuclear Ribonucleoproteins; Lymphoma; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Razoxane; Ribonucleoproteins; T-Lymphocytes; Thymus Gland; Topoisomerase II Inhibitors	1997
Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Cancer research, 1998, Apr-01, Volume: 58, Issue:7 Topics: Amino Acid Sequence; Animals; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Base Sequence; Blotting, Western; CHO Cells; Cricetinae; Diketopiperazines; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Isoenzymes; Molecular Sequence Data; Mutation; Piperazines; Razoxane; Saccharomyces cerevisiae; Topoisomerase II Inhibitors	1998
Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:6 Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Drug Administration Schedule; Etoposide; Female; Mice; Mice, Inbred Strains; Razoxane; Survival Rate; Teniposide; Topoisomerase II Inhibitors	1998
Cytotoxic and DNA-damaging properties of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and its analogues. Biochemical pharmacology, 1998, Aug-01, Volume: 56, Issue:3 Topics: Acridines; Animals; Antineoplastic Agents; DNA; DNA Damage; Enzyme Inhibitors; Etoposide; Mice; Razoxane; RNA; Topoisomerase II Inhibitors	1998
DNA damage signals induction of fas ligand in tumor cells. Molecular pharmacology, 1999, Volume: 55, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; CHO Cells; Cricetinae; DNA; DNA Damage; Doxorubicin; Enzyme Inhibitors; Etoposide; Fas Ligand Protein; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Jurkat Cells; Membrane Glycoproteins; Nucleic Acid Synthesis Inhibitors; Promoter Regions, Genetic; Razoxane; Recombinant Fusion Proteins; Signal Transduction; Teniposide; Thiobarbiturates; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Up-Regulation	1999
Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform. Cancer research, 1999, Jul-15, Volume: 59, Issue:14 Topics: Adenosine Triphosphate; Amino Acid Sequence; Amino Acid Substitution; Amsacrine; Animals; Antineoplastic Agents; Binding Sites; Carcinoma, Small Cell; Catalysis; CHO Cells; Consensus Sequence; Cricetinae; Cricetulus; DNA Damage; DNA Mutational Analysis; DNA Topoisomerases, Type II; DNA, Neoplasm; DNA, Single-Stranded; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Lung Neoplasms; Molecular Sequence Data; Mutagenesis, Site-Directed; Point Mutation; Protein Isoforms; Razoxane; Recombinant Fusion Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Thiobarbiturates; Topoisomerase II Inhibitors; Tumor Stem Cell Assay	1999
Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses. Molecular pharmacology, 2000, Volume: 57, Issue:2 Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; DNA Fragmentation; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Complementary; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; G2 Phase; Humans; Isoenzymes; Mitosis; Promoter Regions, Genetic; Razoxane; RNA, Messenger; S Phase; Sequence Analysis; Topoisomerase II Inhibitors; Tumor Cells, Cultured	2000
N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance. FEBS letters, 2000, Sep-01, Volume: 480, Issue:2-3 Topics: Adenosine Triphosphate; Amsacrine; Antigens, Neoplasm; Diketopiperazines; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance; Enzyme Inhibitors; Etoposide; Humans; Isoenzymes; Mutagenesis; Nucleic Acid Synthesis Inhibitors; Piperazines; Razoxane; Topoisomerase II Inhibitors	2000
Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action. Anti-cancer drugs, 2000, Volume: 11, Issue:10 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Diketopiperazines; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Etoposide; Female; Humans; Leukemia P388; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Naphthalenes; Neoplasm Transplantation; Piperazines; Pyrans; Razoxane; Topoisomerase II Inhibitors; Tumor Cells, Cultured	2000
Diminished molecular response to doxorubicin and loss of cardioprotective effect of dexrazoxane in Egr-1 deficient female mice. Canadian journal of physiology and pharmacology, 2001, Volume: 79, Issue:6 Topics: Animals; Antibiotics, Antineoplastic; Cardiovascular Agents; DNA; DNA-Binding Proteins; Doxorubicin; Early Growth Response Protein 1; Etoposide; Female; Gene Expression Regulation; Immediate-Early Proteins; Mice; Phenotype; Razoxane; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription Factors	2001
High-throughput fluorescence flow-injection topoisomerase II inhibition assay. Journal of chromatography. B, Biomedical sciences and applications, 2001, Sep-05, Volume: 760, Issue:2 Topics: Animals; Catalysis; DNA Topoisomerases, Type II; DNA, Kinetoplast; Electrophoresis, Agar Gel; Enzyme Inhibitors; Etoposide; Flow Injection Analysis; Razoxane; Spectrometry, Fluorescence; Topoisomerase II Inhibitors; Trypanosoma	2001
In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:10 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Child; Cisplatin; Cyclosporins; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Indomethacin; Inhibitory Concentration 50; Piperidines; Pyridines; Quinolines; Razoxane; Rhabdomyosarcoma; RNA, Neoplasm; Staurosporine; Time Factors; Tumor Cells, Cultured; Vincristine	2001
Interference with topoisomerase IIalpha potentiates melphalan cytotoxicity. International journal of oncology, 2002, Volume: 20, Issue:2 Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Blotting, Western; Cell Survival; CHO Cells; Chromosomes; Cricetinae; DNA Damage; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Humans; Melphalan; Mutation; Razoxane; Sister Chromatid Exchange; Thiobarbiturates; Time Factors; Topoisomerase II Inhibitors; Tumor Cells, Cultured	2002
Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide. Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:2 Topics: Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Ethylenediamines; Etoposide; Female; Glycine; Half-Life; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Razoxane	2003
Human topoisomerase IIalpha: targeting to subchromosomal sites of activity during interphase and mitosis. Molecular biology of the cell, 2004, Volume: 15, Issue:5 Topics: Antigens, Neoplasm; Autoantigens; Bromodeoxyuridine; Catalytic Domain; Cell Nucleus; Centromere Protein A; Centrosome; Chromosomal Proteins, Non-Histone; DNA Replication; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; HeLa Cells; Heterochromatin; Histone Deacetylases; Humans; Hydroxamic Acids; Interphase; Intranuclear Space; Microscopy, Confocal; Microscopy, Fluorescence; Mitosis; Razoxane; RNA Polymerase II	2004
Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, May-15, Volume: 11, Issue:10 Topics: Anemia; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiovascular Agents; Cell Culture Techniques; Colony-Forming Units Assay; Daunorubicin; Doxorubicin; Etoposide; Female; Leukopenia; Mice; Neutropenia; Razoxane; Thrombocytopenia	2005
Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-15, Volume: 11, Issue:18 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Central Nervous System Neoplasms; Combined Modality Therapy; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Etoposide; Female; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Razoxane; Survival Analysis; Time Factors; Treatment Outcome; Tumor Cells, Cultured	2005
A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs. Molecular pharmacology, 2006, Volume: 70, Issue:5 Topics: Adenosine Triphosphatases; Antigens, Neoplasm; Catalysis; Cell Line; Diketopiperazines; DNA; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; HCT116 Cells; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Models, Molecular; Mutant Proteins; Piperazines; Purines; Quantitative Structure-Activity Relationship; Razoxane; Static Electricity; Topoisomerase II Inhibitors	2006
A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors. Molecular pharmacology, 2008, Volume: 73, Issue:3 Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Catalysis; CHO Cells; Cricetinae; Cricetulus; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; K562 Cells; Leukemia, Erythroblastic, Acute; Models, Chemical; Models, Molecular; Molecular Structure; Nucleic Acid Conformation; Quantitative Structure-Activity Relationship; Razoxane; Static Electricity; Topoisomerase II Inhibitors	2008
Conjugation of human topoisomerase 2 alpha with small ubiquitin-like modifiers 2/3 in response to topoisomerase inhibitors: cell cycle stage and chromosome domain specificity. Cancer research, 2008, Apr-01, Volume: 68, Issue:7 Topics: Antineoplastic Agents; Catalysis; Cell Cycle; Chromatin; Chromosomes, Human; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; HeLa Cells; Humans; Interphase; Mitosis; Poly-ADP-Ribose Binding Proteins; Protein Inhibitors of Activated STAT; Razoxane; Small Ubiquitin-Related Modifier Proteins; Topoisomerase II Inhibitors	2008
Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:4 Topics: Animals; Antineoplastic Agents; Bone Marrow; Chromosome Aberrations; Etoposide; Glutathione; Lipid Peroxidation; Male; Mice; Micronucleus Tests; Oxidative Stress; Razoxane	2009